Fresenius Kabi releases seizure treatment for immediate availability in US

Fresenius Kabi announced the immediate availability of lacosamide injection, an approved treatment option for partial-onset seizures in those aged 17 years and older, in the United States.

Lacosamide injection, a generic equivalent of Vimpat, is available in 200 mg per 20 mL single-dose vials.

“Fresenius Kabi is pleased to provide the clinicians and patients who rely on us with high quality and accessible choices for treating patients with certain seizures,” Fresenius President and CEO John Ducker stated in a company release.

Fresenius Kabi produces lacosamide injection in the U.S., where it has invested in an advanced manufacturing and distribution network dedicated to hospitals and health care systems.

Lacosamide injection is only approved for those aged 17 years and older and is not labeled for pediatric use, the release stated.